The kick-off meeting of the sub center of "phase IIa clinical trial of antinotriol injection in the treatment of acute ischemic stroke" was successfully held
Release time:2021-08-06 Number of views:398

On August 6 and August 31, 2021, a phase IIa clinical trial sub center kick-off meeting of class 1 innovative drug antinotriol injection of Guangzhou saipute Medical Technology Co., Ltd. was successfully held in the Department of Neurology of Zhujiang Hospital of Southern Medical University (Fig. 1) and the Department of Neurology of Sun Yat Sen Memorial Hospital of Sun Yat sen University (Fig. 2). The trial is a randomized, double-blind, placebo-controlled clinical study to explore the safety and efficacy of antinotriol injection in the treatment of acute ischemic stroke (CDE website registration No.: ctr20192127). The successive launch of the sub centers of Zhujiang Hospital and Zhongshan Second Hospital marks that the national multi center research with Beijing Temple of Heaven hospital as the team leader has entered the stage of comprehensive launch and entry. This study will provide key clinical evidence for further confirming the safety of antinotriol in human body, especially in patients with central nervous system diseases, and verifying its neuroprotective mechanism and efficacy. The test is expected to take 18 months, and the research data will be published from the end of 2022 to the beginning of 2023.

"Triol injection" is the core R & D product of Sept. The intended indication is ischemic stroke. It is a project supported by the national 13th five year plan for the creation of major new drugs. The phase I clinical trial was completed in Peking Union Medical College Hospital in 2017. The results show that the product has good pharmacokinetic characteristics, good tolerance and high safety. At present, Sept is comprehensively promoting the phase IIa clinical trial of "antinotriol injection".